Efficacy of thalidomide in the treatment of severe recurrent epistaxis in hereditary hemorrhagic telangiectasia: results of a prospective phase II clinical trail
EHA Library. Invernizzi R. 06/14/14; 55629 Topic: 1De Disorders with telangiectasias (e.g. Rendu-Osler-Weber disease) (For other platelet disorders see section Coagulation)
Disclosure(s): No affiliation
Prof. Rosangela Invernizzi
Prof. Rosangela Invernizzi
Contributions
About this activity
Learning Objectives
This material is reviewed and approved by the ELC Editorial Board
After viewing this presentation the participant will be able to:

• Understand the rationale for antiangiogenic drugs in herdeditary hemorrhagic telangectasia (HHT)
• Adopt a management strategy for HHT patients with recurrent severe epistaxis.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies